Category: Pharmaceuticals

Pharmaceuticals

Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Pharmaceuticals

Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA

The crossover dose optimization study aims to refine the dosing profile of the oral therapy and strengthen the design of the planned phase III development program.

Pharmaceuticals

Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton

It will analyze once-daily and split-dose regimens of the oral orexin 2 receptor agonist in people with narcolepsy type 1 and type 2.

Prescription Drugs

Study: This Assessment Better Captures Daytime Benefits of Insomnia Treatments

Retrospective questionnaires may miss the true impact of treatments on symptoms such as daytime functioning.

Over-the-Counter Treatments

Study: Over 1 in 5 Young Adults Use Cannabis or Alcohol for Sleep Aid

Findings reveal a high reliance on cannabis for sleep onset among adults aged 19 to 30, prompting calls for better clinical screening regarding substance use.

Emerging Compounds

Phase 2 Explore-OSA Trial: Lorundrostat Reduces Blood Pressure But Not AHI in Sleep Apnea Patients

Topline results from the exploratory trial indicate the aldosterone synthase inhibitor did not reduce the apnea-hypopnea index but provided clinically meaningful blood pressure reduction in adults with moderate-to-severe OSA and hypertension.